Nature 393:7276 Belgardt BF, Brning JC (2010) CNS leptin and insulin action in the control of energy homeostasis
Combination incretin therapies Next-generation pharmacological treatments for obesity include combinations of GLP-1 receptor agonists with other enteropancreatic hormones (such as GIP, glucagon and amylin)
Antibiotic potentiation presents a promising approach
Infants, children, pregnant and lactating women, and people who eat a vegan diet are also at higher risk of deficiency
Bathrooms, parked vehicles, and damp storage areas can expose tablets to changing conditions
CagriSema's strategy of combining two proven mechanisms (amylin and GLP-1) in a single injection has produced strong Phase 3 results (20.4% weight loss), builds on the established semaglutide safety record, and is closest to market with an NDA filed